Breaks Categories: News

TuesdayFeb 14, 2017 12:26 pm

NetworkNewsBreaks – Amended Collaboration Pushes Agenus, Inc. (NASDAQ: AGEN), Incyte Corp. (NASDAQ: INCY) Shares Higher

Agenus (NASDAQ: AGEN) and Incyte (NASDAQ: INCY) are both trading higher this morning after the companies announced the amendment of an agreement signed in January, changing the ongoing GITR and OX40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs. While Incyte is now responsible for funding as well as global development and commercialization, Agenus would now become eligible to receive 15 percent royalties on global net sales of each product if candidates from either of these two programs are approved. Per the amendment, Agenus will receive today accelerated milestone payments of $20 million from Incyte related to…

Continue Reading

TuesdayFeb 14, 2017 12:05 pm

NetworkNewsBreaks – Net Element’s (NASDAQ: NETE) Digital Provider Expands Direct Carrier Billing Services into Poland and Turkey

Global payment technology provider Net Element, Inc. (NASDAQ: NETE) this morning announced that Digital Provider has expanded its Direct Carrier Billing (DCB) services into the emerging markets of Poland and Turkey, giving it access to the two markets’ approximately 113.5 million combined mobile users. Digital Provider’s DCB services could offer numerous benefits for content providers and aggregators in both Poland and Turkey. According to Juniper Research, DCB in emerging markets generates app-store conversion rates that are roughly five times higher than similar figures for credit cards, while SuperData Research estimates that carrier billing is currently the second most popular payment…

Continue Reading

TuesdayFeb 14, 2017 11:13 am

NetworkNewsBreaks – Stealth Technologies, Inc. (STTH) CEO Featured in Exclusive Audio Interview with NetworkNewsWire

Multifaceted financial news and publishing company NetworkNewsWire this morning announced the availability of a new audio interview with Stealth Technologies, Inc. (OTCQB: STTH) CEO Brian McFadden. In the interview, which can be heard at http://NNW.fm/STTH-Interview-Feb-2017, McFadden offers prospective investors some insight into the company’s business model, as well as its flagship product, Stealth Card. Leveraging STTH’s proprietary PowerGrid Technology, Stealth Card is designed to protect consumers’ RFID-chipped credit cards from a practice known as “electronic pickpocketing.” This product, alongside the company’s 911 Help Now emergency alert system, has proven instrumental to Stealth Technologies’ recent growth. “In 2016, Stealth Technologies hit…

Continue Reading

TuesdayFeb 14, 2017 10:31 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Lands New Partnership with Five-Star Hospital in California

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) this morning announced the expansion of its ongoing pilot program to include one of the top five highest-volume orthopedic hospitals in the United States. Notably, the customer is currently rated a five-star hospital by the U.S. Centers for Medicare and Medicaid. In addition to deepening the company’s presence in California and supporting its commitment to reducing national health care costs, this new partnership increases ORHub’s penetration on the West Coast to include more than 50 hospitals. “Even as a top ranking surgery center, this customer is intrigued by the productivity and insight…

Continue Reading

TuesdayFeb 14, 2017 9:44 am

NetworkNewsBreaks – Data from CytoDyn’s (CYDY) Ongoing Phase 2b Extension Study of PRO 140 to be Presented at CROI 2017

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that data from its ongoing Phase 2b extension study with PRO 140 as a monotherapy for the treatment of HIV-infected patients will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. The company’s data will be the subject of a poster presentation on February 15 before being featured in a Themed Discussion on February 16. Dr. Kush Dhody, Senior Director, Clinical Operations at Amarex Clinical Research, is scheduled to make the presentation and participate in the discussion on CytoDyn’s behalf. For those unable to attend the conference,…

Continue Reading

MondayFeb 13, 2017 10:49 am

NetworkNewsBreaks – Micronet (NASDAQ: MICT) Announces New Purchase Order for TREQ®-317

Micronet Enertec Technologies (NASDAQ: MICT) this morning said its Mobile Resource Management (MRM) subsidiary, Micronet Inc., has received a purchase order valued at approximately $800,000 from a leading American school bus fleet management solutions provider for the company’s all-in-one TREQ®-317. TREQ®-317 is an Android tablet designed to improve efficiency, manage the time and attendance of K-12 fleet drivers, improve vehicle maintenance by using the engine diagnostics and fault code alerts, optimize bus routes, and manage student ridership. The company expects to fulfill the order during the second quarter of 2017. "This marks Micronet's first order for our all-in-one TREQ®-317 product…

Continue Reading

MondayFeb 13, 2017 10:08 am

NetworkNewsBreaks – Zosano Pharma Corp.’s (NASDAQ: ZSAN) M207 Meets Co-primary Endpoints in Efficacy Trial; Shares Skyrocket

Shares of Zosano Pharma (NASDAQ: ZSAN) soared more than 100% this morning on news that the company’s lead product candidate, M207, achieved both co-primary endpoints in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study compared three doses (1.0mg, 1.9mg and 3.8mg) of M207, a novel transdermal therapeutic, to placebo for a single migraine attack. The 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and one hour and showed durability of effect on pain freedom at 24 and 48 hours. Overall, higher pain freedom rates were achieved on all doses after 60 minutes…

Continue Reading

MondayFeb 13, 2017 9:20 am

NetworkNewsBreaks – ChineseInvestors.com (CIIX) Issues Update on Recent Financial and Business Achievements

ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning issued a news release highlighting some of its financial and business achievements for January 2017, as well as its plans to build on these milestones moving forward. After reporting significantly higher revenues for the three- and six-month periods ended November 30, 2016, the company has now achieved revenue growth for three consecutive quarters, and ChineseInvestors.com will look to continue this trend through its entry into the hemp-based cannabidiol (CBD) health products market. In addition to completing a $5 million private placement, the company kicked off 2017 with the launch of its new www.ChineseCBDoil.com site,…

Continue Reading

FridayFeb 10, 2017 12:39 pm

NetworkNewsBreaks – MediWound Ltd. (NASDAQ: MDWD) Still Inching Higher on Positive NexoBrid Results

Shares of MediWound (NASDAQ: MDWD) are ticking higher a day after the company reported positive results from its phase 2 study evaluating the safety, pharmacokinetics (transcutaneous absorption) and efficacy of NexoBrid in hospitalized children and adults with severe thermal burns. As a topically administered eschar removal agent, NexoBrid provides a much needed alternative to surgical excision. Surgery of large surfaces of eschar is often limited by the availability of the extensive donor site required. Additionally, surgical excision results in significant surgical burden on these very severe patients including immense blood loss. The phase 2 study included 36 patients with severe…

Continue Reading

ThursdayFeb 09, 2017 1:05 pm

NetworkNewsBreaks – Viking Therapeutics, Inc. (NASDAQ: VKTX) Shares Reverse from Early Rally on Positive Initial Data from VK2809 Study

Shares of Viking Therapeutics (NASDAQ: VKTX) are trading lower, pulling back from a pre-market surge of 10% after the company announced positive initial results from a proof-of-concept study of VK2809 for the treatment of GSD Ia, a rare orphan genetic disease. The data demonstrates that treatment with VK2809 led to statistically significant reductions in key metabolic markers of GSD Ia, including rapid and substantial reductions in liver triglyceride content, liver weight and liver weight as a percentage of body weight, as compared with vehicle-treated controls. "These initial proof-of-concept data showing VK2809's activity in this model of GSD Ia are very…

Continue Reading